Background. It is widely assumed that the graft-enhancing properties of antilymphocyte induction agents and their lymphoma-inducing potential are intimately related. Methods. The Collaborative Transplant Study (CTS) database was used to evaluate graft survival and non-Hodgkin lymphoma at 3 years according to type of induction in 112,122 patients receiving a deceased-donor renal transplant during 1985 to 2004. Results. The relative risk of 3-year graft loss versus no induction was 1.07 (95% confidence interval [CI], 1.01-1.13; Pϭ0.016) with murine anti-CD3 monoclonal antibody (OKT3), 1.03 (95% CI, 0.95-1.11; NS) with antithymocyte globulin (ATG)-Fresenius, 1.18 (95% CI, 1.02-1.35; Pϭ0.021) with ATGAM, 0.74 (95% CI, 0.68 -0.81; PϽ0.001) with Thymoglobulin, and 0.78 (95% CI, 0.72-0.84; PϽ0.001) with interleukin (IL)-2RA induction. The standardized incidence ratio of lymphoma compared with a similar nontransplant population was 21.5 (95% CI, 15.7-28.8; PϽ0.001) with OKT3, 4.9 (95% CI, 1.6 -11.5; Pϭ0.008) with ATG-Fresenius, 29.0 (95% CI, 12.5-57.1; PϽ0.001) with ATGAM, 21.6 (95% CI, 14.3-31.2; PϽ0.001) with Thymoglobulin, 7.8 (95% CI, 4.4 -12.9; PϽ0.001) with IL-2RAs, and 9.4 (95% CI, 8.3-10.6 PϽ0.001) with no induction. Conclusions. Those agents that offered the highest rates of graft survival were not necessarily associated with the highest risk of lymphoma. Graft survival was significantly improved with Thymoglobulin and IL-2RA induction, whereas lymphoma rates were highest with ATGAM, OKT3, and Thymoglobulin. IL-2RA agents seem to offer the best risk-tobenefit ratio for this patient population overall in terms of graft survival and lymphoma.
T he use of induction therapy after renal transplantation has changed in recent years. Murine anti-CD3 monoclonal antibody (OKT3) and horse antithymocyte globulin (ATGAM), which were used widely in the late 1990s, are now used only rarely; rabbit antithymocyte globulin (Thymoglobulin), and interleukin (IL)-2 receptor antagonists (RAs) are currently the most commonly administered induction agents. This switch in prescribing patterns was prompted by the results of randomized clinical trials of 6 or 12 months' duration, which demonstrated improved outcomes and superior tolerability with Thymoglobulin versus ATGAM (1) and a significant reduction in allograft rejection versus placebo with excellent tolerability for IL-2RA agents (2) (3) (4) (5) (6) (7) .
With acute rejection rates now routinely less than 20%, comparisons of immunosuppressive agents are increasingly focused on long-term outcomes (8) . Improving outcomes requires a sensitive balance between achieving effective rejection prophylaxis and avoiding complications such as infection or malignancy that impact on mortality. Clinical trials, however, rarely include adequate patient numbers to detect significant differences in graft survival rates or malignancy and do not generally provide extended follow-up. Long-term data on malignancy rates between different types of induction therapy, in particular, are sparse. Few registry databases collect data on incidence or type of cancer posttransplant. The Collaborative Transplant Study (CTS) obtains malignancy data and validates it for accuracy and completeness with each participating center. Using the CTS database, we previously demonstrated that the risk of non-Hodgkin lymphoma (NHL) was substantially increased with either OKT3 or ATG compared with no induction over a 5-year follow-up period after renal transplantation (9), a finding that was later confirmed in a more recent cohort of patients registered with the CTS (10) . At that time, 12-month follow-up data were available for patients transplanted during 1998 to 2001 who received IL-2RAs, and our preliminary analysis showed that use of this class of induction agents was not associated with an increased risk of lymphoma. The CTS database holds information on the type of induction agent used in a large number of patients, and rates of graft survival and malignancy can now be compared to determine the relative risk of graft loss and lymphoma with specific induction agents in recipients of a renal transplant.
METHODS

Patient Population
Patients who had been reported to the CTS as having received a first kidney transplant from a deceased-donor during the period 1985 to 2004 were eligible for inclusion in the analysis. Patients were categorized according to whether they received OKT3 (Ortho Biotech, Raritan, NJ), ATGAM (Pharmacia & Upjohn, Kalamazoo, MI), ATG-Fresenius S (Fresenius Biotech GmbH, Munich, Germany), Thymoglobulin (Pasteur Merieux Serums et Vaccins, Lyon, France; SangStat Medical Corporation, Menlo Park, CA; Genzyme Transplant, Cambridge, MA), IL-2RA induction (Simulect, Novartis Pharma AG, Basel, Switzerland or Zenapax, Roche Pharmaceuticals, Basel, Switzerland), or no induction. Recipients of retransplants or multiorgan transplants and those who received more than one induction agent were excluded, as were patients in whom the type of induction agent was unknown. Data on graft survival, patient survival, and occurrence of lymphoma were collected at 3, 6, and 12 months during the first year posttransplant and yearly thereafter. Each center was asked to provide annual written confirmation of the accuracy and completeness of lymphoma data to minimize the risk of underreporting, and only patients from those centers that provided this verification were included. In total, 201 centers in 41 countries provided verified data.
All cases of NHL occurring in patients with a functioning graft were analyzed. NHL occurring after graft loss was not analyzed. Only cases with documented NHL were included in the analysis; benign proliferation or hyperplasia were excluded. Incidence of graft loss and NHL were calculated both for the total population and for subpopulations receiving a transplant during 1985 to 1994 or 1995 to 2004, first, because graft outcomes have improved over the 20-year period of data collection, and second, because IL-2RA induction was not widely available until the late 1990s.
Risk Calculation
The relative risk of graft failure was calculated by means of Cox regression analysis. For the standardized incidence ratio of NHL, age, sex, and geographical origin of the recipients were considered and analyzed in relation to a nontransplant background population. Reference frequencies for the rate of NHL in the general population were obtained from the published literature using the closest regional registry data (11) . A normal population of the same size, age distribution (age in 5-year intervals), sex distribution, and geographic distribution to our patient population was generated, and the published frequency was applied to obtain the expected rate of NHL. The standardized incidence ratio (SIR) was calculated by comparing the observed incidence in our study population with the expected incidence in the nontransplant control population. Appropriate consideration was given to the increase of patient age during follow-up, and background incidence rates used for the calculation of SIR were adjusted accordingly. It was ascertained that differences in tumor occurrence ascribed to the use of a particular induction agent were not indirectly attributable to differences in the administration of cyclosporine, tacrolimus, mycophenolic acid, azathioprine, or steroids. All immunosuppressive agents were analyzed according to the intention-to-treat principle.
Statistical Analysis
The Kaplan-Meier method was used to estimate graft survival and cumulative incidence (likelihood) of NHL. The risk of NHL was calculated as the SIR, and analysis based on Poisson distribution was used to estimate the 95% confidence interval (CI) and significance (12) . Cox multivariate regression analysis was used to adjust graft survival rates for potential confounding factors: continent, year of transplant, recipient and donor age, sex, race, human leukocyte antigens (HLA) mismatch, original disease, cold ischemia time, panel reactive antibodies (PRA), and immunosuppressive medication (cyclosporine, tacrolimus, azathioprine, mycophenolic acid, and steroids).
RESULTS
In total, 112,122 patients were included in the analysis, 
Graft Survival
Patients receiving IL-2RA or Thymoglobulin clearly outperformed those receiving no or other induction agents in terms of graft survival at 3 years (Fig. 1) . During 1985 to 1994, when IL2-RAs were not available, induction with Thymoglobulin resulted in the highest graft outcome, whereas in the most recent decade (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) , the highest rates of graft survival were seen in patients receiving either Thymoglobulin or an IL-2RA (Fig. 2) . After adjustment for confounding factors, the relative risk of graft loss was significantly lower with Thymoglobulin and IL-2RA induction than no induction (Table 1) . Graft loss was not significantly different in patients receiving ATG-Fresenius versus no induction, and significantly higher with OKT3 and ATGAM. During 1995 to 2004, there was no appreciable difference in risk of all-cause graft loss between patients receiving Thymoglobulin or IL-2RA induction (Fig. 2) . A similar pattern was observed when deathcensored graft survival was analyzed ( Table 1 ), indicating that variations in graft survival were not secondary to differences in mortality rates between induction therapies. Importantly, however, whereas risk of death was not affected significantly by use of OKT3, ATG-Fresenius, or ATGAM as compared with no induction, the adjusted risk of mortality was significantly lower with either Thymoglobulin or IL-2RAs versus no induction ( Table 1) .
Incidence of Lymphoma
The cumulative three-year incidence of NHL with OKT3 (0.94%; 95% CI, 0.70 -1.26), ATGAM (1.29%; 95% CI, 0.64 -2.57), and Thymoglobulin (1.00%; 95% CI, 0.69 -1.45) was markedly higher than that seen with no induction (0.40%; 95% CI, 0.36 -0.45; Fig. 3 ). In contrast, the incidence of lymphomas in patients receiving ATG-Fresenius (0.24%; 95% CI, 0.10 -0.58) or IL-2RAs (0.36%; 95% CI, 0.21-0.62) was similar to the incidence in patients without an induction. Similar results were seen when the analysis was repeated separately for the periods 1985 to 1994 and 1995 to 2004 (Fig. 4) . High-risk ratios of lymphoma versus nontransplant controls were seen with OKT3 (SIR, 21.5; 95% CI, 15.7-28.8; PϽ0.001), ATGAM (SIR, 29.0; 95% CI, 12.5-57.1; PϽ0.001), and Thymoglobulin (SIR, 21.6; 95% CI, 14.3-31.2; Pϭ0.002) and low relative risks with ATG-Fresenius (SIR, 4.9; 95% CI, 1.6 -11.5; Pϭ0.008) and IL-2RA induction (SIR, 7.8; 95% CI, 4.4 -12.9; PϽ0.001). Among patients receiving no induction, the risk of developing lymphoma by the end of the third year after transplant was 9.4-fold higher than in controls (95% CI, 8.3-10.6; PϽ0.001). When the risk ratio of lymphoma versus controls was compared between treatment groups, OKT3, ATGAM, and Thymoglobulin were each associated with a significantly higher risk than no induction, whereas induction therapy with IL-2RAs or ATG-Fresenius was not associated with an increase in risk ( Table 2 ). The increase in risk was significantly higher with OKT3 (Pϭ0.013) or Thymoglobulin (Pϭ0.027), as compared with IL-2RAs.
DISCUSSION
The results of this analysis indicate that use of an induction agent to reduce the risk of graft loss does not have to be accompanied by an increase in risk of lymphoma. Thymoglobulin and IL-2RAs were associated with the highest rates of 3-year graft survival after renal transplantation from a deceased donor. However, patients receiving Thymoglobulin had a significant increase in risk of lymphoma versus no induction, whereas no increase was seen with IL-2RA induction. Use of OKT3 or ATGAM did not improve graft survival significantly compared to no induction but did lead to a marked increase in risk of lymphoma. ATG-Fresenius did not impact significantly on either graft survival or lymphomas. Patient mortality was lower with either Thymoglobulin or IL-2RA induction versus no induction, but use of OKT3, ATG-Fresenius, or ATGAM had no significant effect on risk of death.
Among patients registered with the CTS since 1995, Thymoglobulin and IL-2RA induction provided significant graft protection in a sizeable proportion of patients, and thus, these agents merit particular attention. Whereas the relative risk of 3-year graft loss was almost identical, the risk of lymphoma was approximately threefold higher with Thymoglobulin than IL-2RA induction at 3 years posttransplant. Accordingly, IL-2RA agents seem to offer a better risk-to-benefit ratio for this patient population in terms of graft survival and incidence of lymphoma. Patient survival, however, was similar in both cohorts.
Our analysis was retrospective in nature, and thus, a degree of caution is appropriate when interpreting the graft survival results or extrapolating them as a measure of the efficacy of antibody induction regimens. Theoretically, the analysis could have been biased because of preferential use of antibody induction in patients considered to be at high immunological risk. However, such a bias is very unlikely to have occurred. The two main reasons for considering patients to be at high immunological risk are rejection of a previous transplant and the presence of pretransplant PRA. Our study did not include any retransplanted patients, and pretrans- plant PRA activity was included as a defined covariable in the Cox analysis. Furthermore, changes in preferential use of different agents over time was accounted for by including the year of transplantation as a covariable in the Cox model. Consistent with our results, randomized trials have shown no significant difference in graft survival rates between patients receiving Thymoglobulin or an IL-2RA (13, 14) . There is a paucity of comparative trials between lymphocytedepleting agents, but a 1-year randomized trial involving 72 renal transplant patients with extended follow-up (15) has shown graft survival to be significantly higher with Thymoglobulin than ATGAM, as was found in our analysis. An analysis of data from more than 38,000 renal transplant recipients registered with the United Network for Organ Sharing-Organ Procurement Transplant Network (UNOS-OPTN) database reported no significant difference in graft survival or lymphoma with polyclonal lymphocyte-depleting antibodies versus no induction, but because there was no distinction between the different polyclonal agents, this is of limited relevance (16) . The same analysis, however, found an improvement in both graft survival and patient survival with IL-2RA therapy versus no induction (16) . A pooled analysis of over 500 patients receiving daclizumab has also reported higher patient survival with IL-2RA induction (98.5% at 1 year versus 95.1% with placebo; Pϭ0.022), although the difference in graft survival did not reach statistical significance (17) . In our analysis, we observed a reduction in mortality risk with either IL-2RA induction or Thymoglobulin.
Randomized clinical trials have inadequate patient numbers to provide robust comparative data on the risk of malignancy with different types of induction, but the available evidence tends to support the results of our analysis. A meta-analysis of seven clinical trials (nϭ1,778) found no increased malignancy with IL-2RAs versus placebo or no induction at 1 year (18), a finding that seems to be sustained for up to 5 years posttransplant (19) . Ducloux et al. (20) used a Cox regression model to analyze data collected retrospectively from 194 renal transplant patients and found that Thymoglobulin carried a higher relative risk of malignancy than ATG-Fresenius, which is consistent with our results. Data from the UNOS-OPTN database has been interrogated to evaluate the risk of posttransplant lymphoproliferative disorder (PTLD) among renal patients receiving a transplant during 1997 to 2000 at a median of 727 days follow-up; the risk of PTLD was higher with OKT3 than with no induction, as found in our analysis, with no significant difference in PTLD using IL-2RAs versus no induction (16) . Polyclonal agents were not analyzed individually.
What could be the reason for the differences in lymphomagenic potential observed for the different antilymphocyte agents? Inhibition of T-cell control, which allows the uninhibited proliferation of B cells, is widely believed to be the underlying mechanism that leads to posttransplant lymphomas. Our finding that Thymoglobulin and ATGAM were associated with high risks of lymphoma is compatible with the broad range of activity of these agents against lymphocyte surface antigens (21). ATG-Fresenius, which is produced by immunization with the Jurkat T-cell line into rabbits, shows a markedly narrower spectrum of activity against lymphocyte antigens than either Thymoglobulin or ATGAM, with no or weak reactivity against CD3, CD4, and CD44 (21) . The monoclonal antibody OKT3, which is specific for the CD3 epitope (22) , is a highly potent agent that blocks both the generation and function of cytotoxic T cells, with T cells virtually disappearing from circulation within hours of OKT3 administration (23) . In contrast, IL-2RA agents exert their immunosuppressive effect via the IL-2 receptor (CD25) (24) , resulting in a specific mechanism of action that affects cells expressing CD25 as a result of an immune response against the transplant. Based on the current results, one might speculate that reactivity against CD3 is associated with lymphomagenicity, whereas reactivity against CD25 is not. In support of this hypothesis, OKT3, ATGAM, and Thymoglobulin are strongly reactive against CD3, whereas ATG-Fresenius possess only weak anti-CD3 activity and IL-2RAs none at all.
Our findings underscore the importance of NHL after renal transplantation. Compared with a nontransplant control population matched for sex, age, and geographical distribution, renal transplant recipients receiving no induction had a ninefold increase in risk of lymphoma by the end of the third year posttransplant, an increase that did not change markedly between the two decades analyzed. With malignancy accounting for approximately 1 in 10 deaths with a functioning graft (25) , selection of immunosuppressive regimens that avoid increasing the risk of lymphoma further should be considered a clinical priority.
CONCLUSIONS
Results from this large-scale, longitudinal analysis of data from recipients of a deceased-donor renal transplant have shown that use of Thymoglobulin or IL-2RA induction is associated with a significant and equivalent improvement in 3-year renal allograft survival. However, the risk of NHL is strikingly higher with Thymoglobulin, ATGAM, and OKT3, whereas there is no increase in lymphoma risk with IL-2RAs or ATG-Fresenius. The prevalence of lymphoma is approximately ninefold higher in renal transplant patients 3 years after transplantation than in a nontransplant population over the same period, and appropriate use of induction therapy seems to represent one strategy to reduce this risk in the future.
